{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:39:04Z","timestamp":1775151544539,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1067\/mjd.2002.119105","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T22:14:26Z","timestamp":1030227266000},"page":"284-293","source":"Crossref","is-referenced-by-count":72,"title":["Cutaneous manifestations of antiretroviral therapy"],"prefix":"10.1067","volume":"46","author":[{"given":"Holly A.","family":"Ward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn G.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Shrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2002.119105_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/34.1.1","article-title":"Drug intolerance in HIV disease","volume":"34","author":"Van der Ven","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1067\/mjd.2002.119105_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00917741","article-title":"Allergic manifestations of human immunodeficiency virus infection","volume":"11","author":"Carr","year":"1991","journal-title":"J Clin Immunol"},{"key":"10.1067\/mjd.2002.119105_bib3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1592\/phco.19.16.1328.30874","article-title":"Indinavir-associated maculopapular eruption","volume":"19","author":"Fung","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1067\/mjd.2002.119105_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0733-8627(20)30375-8","article-title":"Adverse reactions to therapy for HIV infection","volume":"13","author":"Barditch-Crovo","year":"1995","journal-title":"Emerg Med Clin North Am"},{"key":"10.1067\/mjd.2002.119105_bib5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archderm.1991.01680040122017","article-title":"Cutaneous drug reactions in human immunodeficiency virus infection","volume":"127","author":"Coopman","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","article-title":"Cutaneous disease and drug reactions in HIV infection","volume":"328","author":"Coopman","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2002.119105_bib7","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions; a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"10.1067\/mjd.2002.119105_bib8","first-page":"34","article-title":"Adverse drug reactions (ADRs) in patients with HIV infection. A prospective study","volume":"37","author":"Gonzalez-Martin","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1067\/mjd.2002.119105_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0190-9622(99)70452-4","article-title":"Protease inhibitor-induced lipodystrophy","volume":"40","author":"Williamson","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib10","first-page":"2044","volume":"620","author":"Fauci","year":"1998"},{"key":"10.1067\/mjd.2002.119105_bib11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","article-title":"Visceral abdominal-fat accumulation associated with use of indinavir","volume":"351","author":"Miller","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/514639","article-title":"Development of cervical fat pads following therapy with human immunodeficiency virus type I protease inhibitors","volume":"27","author":"Roth","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib13","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/517682","article-title":"Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors","volume":"27","author":"Striker","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib16","doi-asserted-by":"crossref","first-page":"F37","DOI":"10.1097\/00002030-199806000-00001","article-title":"Indinavir-associated lipodystrophy","volume":"12","author":"Viraben","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1086\/514638","article-title":"Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients","volume":"27","author":"Miller","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(05)60294-2","article-title":"\u201cBuffalo hump\u201d in HIV-1 infection","volume":"352","author":"DeLuca","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib19","first-page":"156","article-title":"Multiple symmetrical lipomatosis associated with protease inhibitor therapy","author":"Hengel","year":"1998"},{"key":"10.1067\/mjd.2002.119105_bib20","first-page":"25","article-title":"Protease inhibitor side effects take people by surprise","volume":"12","author":"Huff","year":"1997","journal-title":"GMHC Treat Issues Winter"},{"key":"10.1067\/mjd.2002.119105_bib21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(97)11443-X","article-title":"\u201cBuffalo hump\u201d in men with HIV-1 infection","volume":"351","author":"Lo","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib22","article-title":"Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA summary","author":"Mann","year":"1998"},{"key":"10.1067\/mjd.2002.119105_bib23","article-title":"\u201cProtease-paunch\u201d in HIV+ persons receiving protease inhibitor therapy: incidence, risks, and endocrinologic evaluation","author":"Rosenberg","year":"1998"},{"key":"10.1067\/mjd.2002.119105_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2133.2000.03363.x","article-title":"Lipodsytrophy associated with protease inhibitors","volume":"142","author":"Panse","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(05)75937-7","article-title":"Lipodystrophy in HIV-1 infected patients","volume":"354","author":"Mercie","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(05)77774-6","article-title":"Abnormal fat distribution and use of protease inhibitors","volume":"351","author":"Wurtz","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0190-9622(99)70122-2","article-title":"Striae formation in two HIV-positive persons receiving protease inhibitors","volume":"41","author":"Darvay","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0190-9622(00)90021-5","article-title":"Protease inhibitor-associated angiolipomatosis","volume":"42","author":"Dank","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib29","article-title":"Indinavir enhances retionic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro","author":"Lenhard","year":"1999"},{"key":"10.1067\/mjd.2002.119105_bib30","first-page":"424","article-title":"Inhibition of adipocyte differentiation by HIV protease inhibitors","volume":"11","author":"Zhang","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1067\/mjd.2002.119105_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000018313","article-title":"Paronychia with pyogenic granuloma in a child treated with indinavir: the retinoid-mediated side effect theory revisited","volume":"200","author":"Sass","year":"2000","journal-title":"Dermatology"},{"key":"10.1067\/mjd.2002.119105_bib32","first-page":"365","article-title":"Effects of cytochrome P-450 inhibitors on the in vitro metabolism of all trans-retinoic acid in rats","volume":"252","author":"Van Wauwe","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1067\/mjd.2002.119105_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/abbi.1993.1255","article-title":"Participation of P450 A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation","volume":"303","author":"Martini","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"10.1067\/mjd.2002.119105_bib34","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1097\/00002030-199912240-00023","article-title":"Complete reversibility of severe nucleoside-induced lipodystrophy","volume":"13","author":"Strobel","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00002030-199904160-00020","article-title":"Lipodsytrophy in patients na\u00efve to HIV proteinase inhibitors","volume":"13","author":"Madge","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00002030-199905070-00021","article-title":"Lipodystrophy associated with nevirapine-containing antiretroviral therapies","volume":"13","author":"Aldeen","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-199903110-00004","article-title":"Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy","volume":"13","author":"Gervasoni","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/bmj.318.7176.122","article-title":"Proteases inhibitors in HIV infection. Lipodystrophy may be a consequence of prolonged survival","volume":"318","author":"Buss","year":"1999","journal-title":"BMJ"},{"key":"10.1067\/mjd.2002.119105_bib39","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(99)01172-1","article-title":"Liposuction for protease-inhibitor-associated lipodystrophy","volume":"353","author":"Ponce-de-Leon","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib40","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1097\/00006534-199911000-00032","article-title":"Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use","volume":"104","author":"Wolfort","year":"1999","journal-title":"Plast Reconstr Surg"},{"key":"10.1067\/mjd.2002.119105_bib41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/00002030-199710001-00008","article-title":"Hypersensitivity reactions during antiretroviral regimens with protease inhibitors","volume":"11","author":"Bonfanti","year":"1997","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0899-9007(99)00152-5","article-title":"Effect of protease inhibitors on sense of taste","volume":"15","author":"Schiffman","year":"1999","journal-title":"Nutrition"},{"key":"10.1067\/mjd.2002.119105_bib43","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/00002030-199813000-00015","article-title":"Taste and smell complaints in HIV-infected patients","volume":"12","author":"Heald","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib44","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/archinte.158.19.2160","article-title":"Acute generalized exanthematous pustulosis","volume":"158","author":"Aquilina","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib45","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/00002030-199904010-00013","article-title":"Acute porphyria following commencement of indinavir","volume":"13","author":"Fox","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib46","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1086\/516976","article-title":"Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy","volume":"25","author":"Rietsema","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib47","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/00365549850161322","article-title":"Stevens-Johnson syndrome caused by indinavir","volume":"30","author":"Teira","year":"1998","journal-title":"Scand J Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib48","first-page":"681","article-title":"Gynecomastia during indinavir antiretroviral therapy in HIV infection","volume":"12","author":"Toma","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/597649","article-title":"Hypertrophy of the breasts in a patient treated with indinavir","volume":"25","author":"Herry","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib50","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/00002030-199911120-00015","article-title":"Frozen shoulder in HIV patients treated with indinavir: report of three cases","volume":"13","author":"Peyriere","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib51","first-page":"1657","article-title":"Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor","volume":"11","author":"Carr","year":"1997","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0167-4889(95)00063-X","article-title":"Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator\/plasminogen activator inhibitor-1 complexes in human monocytes","volume":"1268","author":"Simon","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1067\/mjd.2002.119105_bib53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential like between the rennin-angiotensin system and thrombosis","volume":"95","author":"Vaughn","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1067\/mjd.2002.119105_bib54","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM199908193410818","article-title":"Alopecia associated with indinavir therapy","volume":"8","author":"Bouscarat","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2002.119105_bib55","first-page":"328","article-title":"Indinavir-related alopecia","volume":"12","author":"Monforte","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib56","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199806113382417","article-title":"Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir","volume":"338","author":"Bouscarat","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2002.119105_bib57","first-page":"277","article-title":"Indinavir-related recurrent paronychia and ingrown toenails","volume":"64","author":"Alam","year":"1999","journal-title":"Cutis"},{"key":"10.1067\/mjd.2002.119105_bib58","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archderm.135.4.471","article-title":"The changing spectrum of the cutaneous manifestations of HIV disease","volume":"135","author":"Colebunders","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib59","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0190-9622(84)80289-3","article-title":"Paronychia and pyogenic granuloma-like lesions with isotretinion","volume":"4","author":"Blumental","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib60","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archderm.1983.01650340018012","article-title":"Pyogenic granuloma-like acne lesions during isotretinion therapy","volume":"119","author":"Exner","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1085-5629(97)80046-6","article-title":"Current antiretroviral therapy in the treatment of HIV infection","volume":"16","author":"Chopra","year":"1997","journal-title":"Semin Cutan Med Surg"},{"key":"10.1067\/mjd.2002.119105_bib62","first-page":"612","article-title":"Continued therapy with HIV-1 protease inhibitors, despite previous hypersensitivity reactions through coadministration of prednisone","volume":"30","author":"Prins","year":"1998","journal-title":"Scand J Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib63","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/00006454-199810000-00021","article-title":"Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection","volume":"17","author":"Hagerty","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1067\/mjd.2002.119105_bib64","first-page":"388","article-title":"Unusual occurrence of spontaneous hematomas in three asymptomatic HIV-infected heamophilia patients a few days after the onset of ritonavir treatment","volume":"11","author":"Ginsburg","year":"1997","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib65","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1365-2141.1999.01748.x","article-title":"Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders","volume":"107","author":"Wilde","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1067\/mjd.2002.119105_bib66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2516.1998.00154.x","article-title":"Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors","volume":"4","author":"Stanworth","year":"1998","journal-title":"Haemophilia"},{"key":"10.1067\/mjd.2002.119105_bib67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00002030-199818000-00002","article-title":"The Swiss HIV cohort study, the Swiss collaborative HIV and pregnancy study and the Swiss neonatal HIV Study (1998). Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects","volume":"12","author":"Lorenzi","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00041433-199304000-00006","article-title":"The LDL-receptor-related protein: portrait of a multifunctional receptor","volume":"4","author":"Herz","year":"1993","journal-title":"Curr Opin Lipidol"},{"key":"10.1067\/mjd.2002.119105_bib69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.1997.03540260059037","article-title":"HIV-1 protease inhibitors: a review for clinicians","volume":"277","author":"Deeks","year":"1997","journal-title":"JAMA"},{"key":"10.1067\/mjd.2002.119105_bib70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0091-6749(98)70031-4","article-title":"Nelfinavir-induced urticaria and successful desensitization","volume":"102","author":"Demoly","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mjd.2002.119105_bib71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00002030-200002180-00024","article-title":"Rash as a side-effect of nelfinavir in children","volume":"114","author":"Fortuny","year":"2000","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib72","first-page":"29","article-title":"Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor","volume":"66","author":"Smith","year":"2000","journal-title":"Cutis"},{"key":"10.1067\/mjd.2002.119105_bib73","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/00002030-199911120-00016","article-title":"Prednisolone does not prevent the occurrence of nevirapine-induced rashes","volume":"13","author":"Rey","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib74","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00002030-199606000-00009","article-title":"A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemiac HIV-infected patients","volume":"10","author":"Carr","year":"1996","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib75","first-page":"1029","article-title":"Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection","volume":"124","author":"Daquila","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib76","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.279.12.930","article-title":"A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. The INCAS Trial","volume":"279","author":"Montaner","year":"1998","journal-title":"JAMA"},{"key":"10.1067\/mjd.2002.119105_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042560-199901010-00002","article-title":"A randomized, double-blind trial on the use of a triple combination including nevirapine, a non-nucleoside reverse transcriptase HIV inhibitor, in antiretroviral-na\u00efve patients with advanced disease","volume":"20","author":"Florida","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1067\/mjd.2002.119105_bib78","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(05)79417-4","article-title":"Nevirapine and rashes","volume":"351","author":"Barner","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib79","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(98)24008-6","article-title":"Nevirapine-associated Stevens-Johnson syndrome","volume":"351","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib80","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/00002030-199815000-00026","article-title":"High incidence of nevirapine associated rash in HIV-infected Chinese","volume":"12","author":"Ho","year":"1998","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib81","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00002030-199903110-00013","article-title":"Incidence of rash and discontinuation of nevirapine using two different escalating initial doses","volume":"13","author":"Anton","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib82","doi-asserted-by":"crossref","unstructured":"Kaspar R. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998. San Diego, Calif. Program Abstract 1-64a.","DOI":"10.1016\/S1368-7646(98)80016-2"},{"key":"10.1067\/mjd.2002.119105_bib83","first-page":"14","article-title":"AIDS\/HIV Treatment Directory Vol 9","author":"Abrams","year":"1997"},{"key":"10.1067\/mjd.2002.119105_bib84","first-page":"1321","article-title":"DRESS (Drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy","volume":"27","author":"Bourezane","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2002.119105_bib85","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/archderm.1996.03890350057010","article-title":"Drug-induced pseudolymphoma and hypersensitivity syndrome","volume":"132","author":"Callot","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib86","first-page":"552","article-title":"Azidothymidine-induced nail pigmentation","volume":"43","author":"Fisher","year":"1989","journal-title":"Cutis"},{"key":"10.1067\/mjd.2002.119105_bib87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0190-9622(90)70039-K","article-title":"Nail and mucocutaneous hyperpigmentation with azidothymidine therapy","volume":"22","author":"Greenberg","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib88","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archderm.1989.01670210123028","article-title":"Azidothymidine-induced hyperpigmentation of skin and nails","volume":"125","author":"Bendick","year":"1989","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib89","doi-asserted-by":"crossref","first-page":"943","DOI":"10.7326\/0003-4819-107-6-943_2","article-title":"Nail pigmentation in the acquired immunodeficiency syndrome (AIDS)","volume":"107","author":"Panwalker","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib90","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/archderm.1988.01670100068021","article-title":"Zidovudine-induced nail pigmentation","volume":"124","author":"Azon-Masoliver","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib91","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-107-2-350","article-title":"Nail pigmentation changes associated azidothymidine (zidovudine)","volume":"107","author":"Furth","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib92","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-108-5-777_2","article-title":"Nail pigmentation and azidothymidine","volume":"107","author":"Vaiopoulos","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib93","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archderm.1992.01680140088008","article-title":"Selective cutaneous hyperpigmentation in mice following zidovudine administration","volume":"28","author":"Obuch","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib94","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/00002030-199111000-00025","article-title":"Zidovudine-associated hypertrichosis and nail pigmentation in an HIV-infected patient","volume":"5","author":"Sahai","year":"1991","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib95","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJM199106273242616","article-title":"Excessive growth of eyelashes in a patient with AIDS being treated with zidovudine","volume":"324","author":"Klutman","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2002.119105_bib96","article-title":"HIV-associated alopecia in a women and regrowth of hair after zidovudine therapy","author":"Vernazza","year":"1989"},{"key":"10.1067\/mjd.2002.119105_bib97","first-page":"495","article-title":"Zidovudine-induced fever","volume":"100","author":"Jacobson","year":"1984","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1067\/mjd.2002.119105_bib98","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(05)79324-7","article-title":"Lamivudine-induced paronychia","volume":"351","author":"Zerboni","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib99","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1001\/archinte.1988.00380100134031","article-title":"Heightened cutaneous reactions to mosquito bites in patients with acquired immunodeficiency syndrome receiving zidovudine","volume":"148","author":"Diven","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib100","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/archinte.1992.00400160138027","article-title":"Zidovudine-induced leukocytoclastic vasculitis","volume":"152","author":"Torres","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib101","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(94)92111-3","article-title":"Cutaneous vasculitis associated with didanosine","volume":"344","author":"Herranz","year":"1994","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib102","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0140-6736(92)92740-7","article-title":"Didanosine as probable cause of Stevens-Johnson syndrome","volume":"340","author":"Parneix-Spake","year":"1992","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib103","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000246003","article-title":"Dideoxyinosine-associated Ofuji papuloerythroderma in an HIV-infected patient","volume":"195","author":"Just","year":"1997","journal-title":"Dermatology"},{"key":"10.1067\/mjd.2002.119105_bib104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000249586","article-title":"Papuloerythroderma","volume":"168","author":"Ofuji","year":"1984","journal-title":"Dermatologica"},{"key":"10.1067\/mjd.2002.119105_bib105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000247344","article-title":"Papuloerythroderma: report of a European case","volume":"186","author":"Boden","year":"1993","journal-title":"Dermatology"},{"key":"10.1067\/mjd.2002.119105_bib106","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/00002030-199612000-00025","article-title":"Gout secondary to ritonavir and didanosine","volume":"10","author":"Melhaff","year":"1996","journal-title":"AIDS"},{"key":"10.1067\/mjd.2002.119105_bib107","first-page":"12","article-title":"Lamivudine useful in the therapy of HIV infection","author":"Boyles","year":"1996","journal-title":"Antiviral Wkly"},{"key":"10.1067\/mjd.2002.119105_bib108","first-page":"227","article-title":"Lamivudine (3TC)-induced contact dermatitis","volume":"65","author":"Smith","year":"2000","journal-title":"Cutis"},{"key":"10.1067\/mjd.2002.119105_bib109","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0190-9622(99)70476-7","article-title":"Severe paronychia due to zidovudine-induced neutropenia in a neonate","volume":"40","author":"Russo","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib110","first-page":"24","volume":"9","author":"Abrams","year":"1997","journal-title":"AIDS\/HIV Treatment Directory"},{"key":"10.1067\/mjd.2002.119105_bib111","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0190-9622(89)70332-7","article-title":"Dermatologic complications associated with administration of 2\u2032,3\u2032-dideoxycytidine in patients with human immunodeficiency virus infection","volume":"21","author":"McNeely","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.119105_bib112","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)91459-2","article-title":"Hypersensitivity syndrome associated with zalcitabine","volume":"347","author":"Tancrede-Bohin","year":"1996","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(88)90283-8","article-title":"Phase I studies of 2,3-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine","volume":"1","author":"Yarchoan","year":"1988","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.119105_bib114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7326\/0003-4819-122-1-199501010-00004","article-title":"Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease","volume":"122","author":"Fischl","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2002.119105_bib115","unstructured":"Liebermann J, Nauss-Karol C, Salgo M, et al. Safety experience with dideoxycytidine (ddc) in an expanded access population. Ninth International Conference on AIDS; June 1993; Berlin, Germany. Program Abstract PO-B-3004."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962202192723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962202192723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:42:30Z","timestamp":1620002550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962202192723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0190962202192723"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2002.119105","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}